[
  {
    "ts": null,
    "headline": "Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion",
    "summary": "Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.”",
    "url": "https://finnhub.io/api/news?id=88de1d185474d9a657b01837408a5d192f7386238fe7090eeb8aa1a99bc1059e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763403600,
      "headline": "Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion",
      "id": 137506320,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.”",
      "url": "https://finnhub.io/api/news?id=88de1d185474d9a657b01837408a5d192f7386238fe7090eeb8aa1a99bc1059e"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment",
    "summary": "Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.",
    "url": "https://finnhub.io/api/news?id=6dea7c67797e550ae7f14b427d99e2f00f1bb7467b5e137ee96962968e239e97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763401457,
      "headline": "Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment",
      "id": 137506321,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.",
      "url": "https://finnhub.io/api/news?id=6dea7c67797e550ae7f14b427d99e2f00f1bb7467b5e137ee96962968e239e97"
    }
  },
  {
    "ts": null,
    "headline": "3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List",
    "summary": "The best healthcare stocks from Goldman Sachs' list that are also Quant Strong Buys have attractive valuations and forward earnings growth potential. Click here to see the top 3 stocks.",
    "url": "https://finnhub.io/api/news?id=74c02aacfdcf6b179b4f6d9ada5443e306b4c5674ecc95adbf719a39d4ecc8ed",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763395539,
      "headline": "3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List",
      "id": 137508603,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2197655235/image_2197655235.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The best healthcare stocks from Goldman Sachs' list that are also Quant Strong Buys have attractive valuations and forward earnings growth potential. Click here to see the top 3 stocks.",
      "url": "https://finnhub.io/api/news?id=74c02aacfdcf6b179b4f6d9ada5443e306b4c5674ecc95adbf719a39d4ecc8ed"
    }
  },
  {
    "ts": null,
    "headline": "2 Giant Healthcare Stocks to Buy Hand Over Fist in November",
    "summary": "Consider buying Medtronic for its dividend and Pfizer for its turnaround potential if you are looking for attractive healthcare investments in November.",
    "url": "https://finnhub.io/api/news?id=3aa3aefc8bdf4ab5aa82ff886790c7a639e9d1d352a30e84c92343f9458d571d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763391600,
      "headline": "2 Giant Healthcare Stocks to Buy Hand Over Fist in November",
      "id": 137506513,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Consider buying Medtronic for its dividend and Pfizer for its turnaround potential if you are looking for attractive healthcare investments in November.",
      "url": "https://finnhub.io/api/news?id=3aa3aefc8bdf4ab5aa82ff886790c7a639e9d1d352a30e84c92343f9458d571d"
    }
  },
  {
    "ts": null,
    "headline": "MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026",
    "summary": "Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.",
    "url": "https://finnhub.io/api/news?id=e7f19a92ec4c599d1427d885c40fb20427a4ed9c6a76e26d88e16fbe9a0edef7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763386380,
      "headline": "MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026",
      "id": 137506439,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.",
      "url": "https://finnhub.io/api/news?id=e7f19a92ec4c599d1427d885c40fb20427a4ed9c6a76e26d88e16fbe9a0edef7"
    }
  },
  {
    "ts": null,
    "headline": "PLX: Protalix Seeks Re-Examination of CHMP Opinion",
    "summary": "By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2025 Financial and Operational Review Protalix BioTherapeutics, Inc. (NYSE:PLX) announced 3Q:25 financial and operational results in a November 13 th , 2025, press release and in its Form 10-Q filing. The reports were followed by a conference call, which discussed recent achievements, regulatory updates, trial",
    "url": "https://finnhub.io/api/news?id=c877314b252efae77608f86ee76917f71806dd857856374ae609240b5a6cca4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763375220,
      "headline": "PLX: Protalix Seeks Re-Examination of CHMP Opinion",
      "id": 137506515,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2025 Financial and Operational Review Protalix BioTherapeutics, Inc. (NYSE:PLX) announced 3Q:25 financial and operational results in a November 13 th , 2025, press release and in its Form 10-Q filing. The reports were followed by a conference call, which discussed recent achievements, regulatory updates, trial",
      "url": "https://finnhub.io/api/news?id=c877314b252efae77608f86ee76917f71806dd857856374ae609240b5a6cca4b"
    }
  },
  {
    "ts": null,
    "headline": "iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector",
    "summary": "The biotech sector, tracked by iShares Biotechnology ETF, rallied 40% in six months on rising M&A activity, still below four-year levels. Read why IBB ETF is a hold.",
    "url": "https://finnhub.io/api/news?id=a93c9f715820a416f957440d371d00b46609b15bee750a6ce8d107460a587075",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763372660,
      "headline": "iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector",
      "id": 137504722,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184964962/image_184964962.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The biotech sector, tracked by iShares Biotechnology ETF, rallied 40% in six months on rising M&A activity, still below four-year levels. Read why IBB ETF is a hold.",
      "url": "https://finnhub.io/api/news?id=a93c9f715820a416f957440d371d00b46609b15bee750a6ce8d107460a587075"
    }
  },
  {
    "ts": null,
    "headline": "Down 55%, Should You Buy the Dip on Pfizer?",
    "summary": "Pfizer is a pharmaceutical industry giant facing normal pharmaceutical industry headwinds; it will survive.",
    "url": "https://finnhub.io/api/news?id=01347b22d1a8d118419c1173b600f440b128fa8d041d579b223a1e03e530d084",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763372100,
      "headline": "Down 55%, Should You Buy the Dip on Pfizer?",
      "id": 137504218,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is a pharmaceutical industry giant facing normal pharmaceutical industry headwinds; it will survive.",
      "url": "https://finnhub.io/api/news?id=01347b22d1a8d118419c1173b600f440b128fa8d041d579b223a1e03e530d084"
    }
  }
]